Arc­turus Ther­a­peu­tics hand­ed $115M from Japan­ese gov­ern­ment to de­vel­op pro­duc­tion site

San Diego-based RNA biotech Arc­turus Ther­a­peu­tics’ man­u­fac­tur­ing op­er­a­tions in Japan have been giv­en a fi­nan­cial boost from the lo­cal gov­ern­ment.

Ar­calis Co., Ltd., its pro­duc­tion op­er­a­tion, is a joint ven­ture be­tween Arc­turus and Tokyo-based drug dis­cov­ery com­pa­ny Ax­ce­lead. Ar­calis has re­ceived $115 mil­lion in two grants from the Japan­ese gov­ern­ment. Ar­calis is re­spon­si­ble for man­u­fac­tur­ing mR­NA-based vac­cines and med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER